2. Academic Validation
  3. A non-crosslinking platinum-acridine hybrid agent shows enhanced cytotoxicity compared to clinical BCNU and cisplatin in glioblastoma cells

A non-crosslinking platinum-acridine hybrid agent shows enhanced cytotoxicity compared to clinical BCNU and cisplatin in glioblastoma cells

  • Bioorg Med Chem Lett. 2005 Jan 17;15(2):443-6. doi: 10.1016/j.bmcl.2004.10.049.
Suzanne M Hess 1,  Joel G Anderson,  Ulrich Bierbach
Affiliations

Affiliation

  • 1 Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
PMID: 15603970 DOI: 10.1016/j.bmcl.2004.10.049
Abstract

Using clonogenic survival assays, we demonstrated that a new platinum-acridine hybrid agent, PT-ACRAMTU, is cytotoxic in SNB19 and U87MG glioblastoma cells at low-micromolar concentrations. PT-ACRAMTU is more cytotoxic than ACRAMTU (the platinum-free acridine), acts in a time and dose dependent manner, and appears to generate an apoptotic response in both cell lines on the basis of increased Caspase-3 activity.

Figures